Trial · NCT02378805
Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
NCT02378805, Recruiting, University Hospital Goettingen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome. Trials, record NCT02378805. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02378805
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
- NCT number
- NCT02378805
- Status
- Recruiting
- Enrollment
- 800 participants, estimated
- Lead sponsor
- University Hospital Goettingen
- Conditions
- Alport Syndrome, Hereditary Kidney Disease, Pediatric Kidney Disease, Thin Basement Membrane Disease, Familial Benign Hematuria
- Interventions
- ACE-inhibitor, Angiotensin-receptor blocker (ARB), HMG-Coenzyme inhibitor (statin), Spironolactone or Finerenone, Paricalcitol, SGLT2 inhibitor
- First posted
- 2015-03-04
- Last updated
- 2025-03-06
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | age at onset of end stage kidney failure (need for renal replacement therapy) | until end of observation in 2037 | kidney disease in Alport syndrome starts at birth, age at onset of end stage kidney failure in years |
| Primary | life-expectancy in years (age at death) | until end of observation in 2037 | Alport syndrome starts at birth, age at death of patients in years |
| Primary | yearly loss of estimated glomerular filtration rate (eGFR) | until end of observation in 2037 | kidney disease in Alport syndrome starts at birth, eGFR-loss per year in ml/min/1.73m2 |
| Primary | time in years until doubling or tripling of urinary albumin to creatinine ratio (UACR) | until end of observation in 2037 | kidney disease in Alport syndrome starts at birth; time since birth to doubling (AS stages I or II) or tripling (AS stage 0) of UACR in years. |
| Secondary | amount of albuminuria over time | until end of observation in 2037 | kidney disease in Alport syndrome starts at birth; change in albuminuria after birth |
| Secondary | amount of proteinuria over time | until end of observation in 2037 | kidney disease in Alport syndrome starts at birth; change in proteinuria after birth |
| Secondary | number of patients with X-chromosomal or autosomal inheritance | until end of observation in 2037 | specific genetic variant: X-linked, digenic, autosomal heterozygous, homozygous, compound heterozygous |
| Secondary | number of patients experiencing side effects (AEs) | until end of observation in 2037 | AEs of special interest: acute kidney renal failure, angioedema, hyperkalemia, dry cough, symptomatic hypotension (orthostatic collapse) and others, and death from all causes. |
| Secondary | number of patients with hearing loss | until end of observation in 2037 | Alport syndrome is a genetic disease, hearing loss delevops over time since birth |
| Secondary | number of patients with eye involvement | until end of observation in 2037 | Alport syndrome is a genetic disease, eye symptoms delevop over time since birth |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers11
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02378805
GET https://conductscience.org/api/trials/v1/NCT02378805/registered